Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics, retaining the price target of $24.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Capricor Therapeutics’ regulatory progress and strategic positioning. The recent Type A meeting with the FDA provided encouraging insights into the path forward for deramiocel’s BLA resubmission, particularly with the HOPE-3 clinical trial being accepted as an additional study. This trial’s data, which will be included in the BLA, aims to address both cardiac and skeletal muscle functions in DMD, with the potential for regulatory flexibility from the FDA.
Furthermore, despite some anticipated delays, Capricor’s robust financial position and strong partnership with Nippon Shinyaku bolster confidence in deramiocel’s future market launch. The company’s proactive approach in addressing all CMC issues identified in the CRL and the anticipated release of HOPE-3 topline data in late 2025 further support Pantginis’s optimistic outlook. These strategic and regulatory advancements underpin the Buy rating, reflecting optimism about Capricor’s ability to navigate the regulatory landscape successfully.
In another report released today, JonesTrading also maintained a Buy rating on the stock with a $29.00 price target.